Oncolytics Biotech Data Signal Registration Path for Pelareorep Combo in Third-Line Anal Cancer

An announcement from Oncolytics Biotech ( (ONCY) ) is now available.

Oncolytics Biotech reported updated data from its GOBLET Cohort 4 trial showing that the combination of pelareorep and Roche’s checkpoint inhibitor atezolizumab achieved an objective response rate of about 29% in highly pretreated third-line metastatic squamous cell anal carcinoma patients, nearly tripling historical response rates of around 10% or less in a setting with no approved therapies. With two complete and two partial responses and a median duration of response of roughly 17 months—alongside previously reported strong second-line results versus the current standard of care—the company sees a clear path toward a registration study and is positioning pelareorep plus atezolizumab as a potentially practice-changing option in a rare, high-unmet-need indication, while it engages the FDA on an accelerated approval strategy.

The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is driven primarily by weak financial performance (no revenue, large losses, heavy cash burn) and heightened balance-sheet strain from sharply reduced equity. Technical indicators also point to a weak trend and bearish momentum. Valuation provides only limited support because the negative P/E reflects ongoing losses and there is no dividend yield provided.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapy designed to turn immunologically “cold” tumors “hot” by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors across metastatic pancreatic and breast cancers—both with FDA Fast Track designation—as well as other gastrointestinal tumors, and is seeking strategic partnerships to accelerate development and commercialization.

Average Trading Volume: 728,620

Technical Sentiment Signal: Sell

Current Market Cap: $106.7M

For an in-depth examination of ONCY stock, go to TipRanks’ Overview page.